EL7.AI
StocksMedium•16 November 2026•
4 min read

FDA approves Wilserdly and everolimus combination, doubling median progression-free survival

Key Facts

1On November 16, 2026, the FDA approved giredestrant with everolimus for patients with advanced estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation.
2Median progression-free survival was 10 months with the combination, versus 5.5 months with the comparator treatment; objective response rates were 27% versus 14%.
3The hazard ratio for disease progression or death was 0.38, with statistical significance at p<0.0001.
4The FDA authorized the FoundationOne Liquid CDx test to identify patients with ESR1 mutations who are eligible for treatment.
5The FDA set November 30, 2026, as the target date for a decision on the application for giredestrant as adjuvant treatment for early breast cancer.

The U.S. Food and Drug Administration on November 16, 2026, approved giredestrant, marketed as Wilserdly, with everolimus to treat adults with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer whose tumors have an ESR1 mutation detected by an approved test. The approval includes patients whose disease returned during or after adjuvant endocrine therapy, as well as those whose disease progressed after at least one endocrine regimen in the metastatic setting. The decision covers the drug combination, not giredestrant alone. According to the FDA, results from the evERA trial showed median progression-free survival of 10 months with the combination among patients with the mutation, versus 5.5 months with everolimus and physician’s choice of endocrine therapy. The combination also recorded an objective response rate of 27%, compared with 14% in the control group.

The open-label, multicenter, randomized evERA trial evaluated treatment in 373 adults, including 207 patients whose tumors carried ESR1 mutations. In the mutation-positive group, the study compared giredestrant and everolimus with physician’s choice of endocrine therapy plus everolimus, making the comparison one between two regimens that shared the same companion drug. Median progression-free survival was 10 months in the giredestrant group, versus 5.5 months in the control group. The objective response rate, meaning tumor responses recorded under the study’s criteria, was 27% with the new combination and 14% with the comparator treatment. The hazard ratio for disease progression or death was 0.38 in the ESR1 group, a statistically significant result with a p-value of <0.0001. Overall survival data were immature when progression-free survival was analyzed.

The FDA describes giredestrant as an estrogen receptor antagonist, while developer Genentech describes it as a selective estrogen receptor degrader. The drug is taken orally, but it is not used alone under the approval; the authorized regimen combines it with everolimus. ESR1 mutation status remains central to determining patient eligibility, alongside estrogen receptor positivity, HER2 negativity, disease stage and the history of prior endocrine therapy. The FDA authorized the FoundationOne Liquid CDx test as a companion diagnostic to identify patients with ESR1 mutations who are eligible for treatment. This limits the decision’s scope to a defined group of patients rather than extending it to all cases of advanced breast cancer.

The most common adverse reactions with giredestrant and everolimus included stomatitis, rash, fatigue, diarrhea and musculoskeletal pain. The list also included lung and breathing effects and nausea among the effects monitored by the FDA. The prescribing information carries warnings about bradycardia and embryo-fetal toxicity. These considerations are part of the information accompanying the approved use of the combination. The approval decision therefore also specified the warnings that should accompany prescribing the treatment.

The FDA reviewed the application under Project Orbis in collaboration with Health Canada and the Israeli Ministry of Health. The agency said the approval came four weeks before the target date. Alongside the decision on treatment for advanced disease, the FDA is reviewing a separate application for giredestrant as adjuvant treatment for early breast cancer. The company set November 30, 2026, as the target date for a decision on that application. The date marks a subsequent regulatory milestone for a use different from the combination approved on November 16.

Genentech said hormone receptor-positive, HER2-negative breast cancer accounts for about 70% of breast cancer cases. The company linked resistance to endocrine therapies, particularly after CDK inhibitors, to an increased risk of disease progression. It described the evERA results as the first positive Phase 3 readout for the giredestrant program, followed by results from the lidERA study in early breast cancer. These results place the drug program in a broader context than the November decision on its use in advanced disease. The next specified regulatory step remains the FDA’s targeted November 30 decision on the adjuvant application.